The tirzepatide switch Mounjaro patients are quietly making, for a fraction of the price
Same active compound. Same weekly injection. Around £100 a month cheaper than a branded Mounjaro KwikPen for most people, with needles, dietitian access and support included.
Why patients are switching
If you are paying a UK pharmacy for Mounjaro, the bill climbs with every dose increase. At 5mg a week it is around £199 a month. At 7.5mg it is around £249. By 10mg you are close to £279 a month, over £3,300 a year. For a lot of people, that is the point where staying on treatment starts to feel like a stretch.
Tirzepatide, the active compound in Mounjaro, is now available in the UK through regulated providers as a pre-filled weekly pen or a lower-cost vial. The mechanism is identical: the same dual GIP/GLP-1 receptor agonist action, the same weekly injection, the same titration from 2.5mg upwards. What is different is the supply chain, and that is what drives the price.
A Mounjaro KwikPen holds four weekly doses. So the 2.5mg KwikPen is actually 10mg of tirzepatide in total, for around £169 at a typical pharmacy. That works out at roughly £17 per mg. An Elva 90mg pen works out at about £4.40 per mg, and a single 10mg vial is £71.99.
The saving is largest at the lower doses, where the Mounjaro KwikPen is most expensive per mg. At 2.5mg a week the difference works out at over £1,400 a year, and even at 5mg it is over £1,200. The 90mg pen stays the best value right across the dose range. The assessment runs that comparison for your exact dose and format.